Kintz Samuel 4
4 · Enliven Therapeutics, Inc. · Filed Aug 20, 2025
Insider Transaction Report
Form 4
Kintz Samuel
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2025-08-19$20.00/sh−590$11,800→ 929,409 total(indirect: See footnote) - Sale
Common Stock
2025-08-18$20.02/sh−10,393$208,106→ 929,999 total(indirect: See footnote)
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $19.75 to $20.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.